Neural correlates of improved recognition of happy faces after erythropoietin treatment in bipolar disorder

Research output: Contribution to journalJournal articleResearchpeer-review

Kamilla Woznica Miskowiak, N A Petersen, C J Harmer, E Ehrenreich, Lars Vedel Kessing, Maj Vinberg, Julian Macoveanu, Hartwig Roman Siebner

OBJECTIVE: Bipolar disorder is associated with impairments in social cognition including the recognition of happy faces. This is accompanied by imbalanced cortico-limbic response to emotional faces. We found that EPO improved the recognition of happy faces in patients with bipolar disorder. This randomized, controlled, longitudinal fMRI study explores the neuronal underpinnings of this effect.

METHOD: Forty-four patients with bipolar disorder in full or partial remission were randomized to eight weekly erythropoietin (EPO; 40 000 IU) or saline (NaCl 0.9%) infusions in a double-blind, parallel-group design. Participants underwent whole-brain fMRI at 3T, mood ratings and blood tests at baseline and week 14. During fMRI, participants viewed happy and fearful faces and performed a gender discrimination task.

RESULTS: Thirty-four patients had complete pre- and post-treatment fMRI data (EPO: N = 18, saline: N = 16). Erythropoietin vs. saline increased right superior frontal response to happy vs. fearful faces. This correlated with improved happiness recognition in the EPO group. Erythropoietin also enhanced gender discrimination accuracy for happy faces. These effects were not influenced by medication, mood, red blood cells or blood pressure.

CONCLUSIONS: Together with previous findings, the present observation suggests that increased dorsal prefrontal attention control is a common mechanism of EPO-associated improvements across several cognitive domains.

Original languageEnglish
JournalActa Psychiatrica Scandinavica
Volume138
Issue number4
Pages (from-to)336-347
Number of pages12
ISSN0001-690X
DOIs
Publication statusPublished - Oct 2018

    Research areas

  • bipolar disorder, neurocognition, neuroimaging, randomized controlled trial

ID: 203247935